BW Offshore: Extension agreement for Cidade de São Vicente

Written by Customer Service on June 6, 2020. Posted in Public Companies.

Extension agreement for Cidade de São VicenteBW Offshore has received a notice from Petrobras extending the lease and operation agreement of BW Cidade de São Vicente with 120 days. With this the contract will expire on 9 October 2020.BW Offshore has commenced planning for demobilisation of the unit from the field and is considering temporary lay up in Brazil.BW Cidade de São Vicente commenced operation for Petrobras in 2009 and has been utilised as a well test facility for the client on multiple locations offshore Brazil.For further information, please contact:Ståle Andreassen, CFO, +65 97 27 86 47Anders S. Platou, Head of Corporate Finance, +47 99 50 47 40IR@bwoffshore.com or www.bwoffshore.comAbout BW Offshore:BW Offshore is a leading provider of floating production services to the oil and gas industry. The company also participates...

Medienmitteilung | MCH Group | Art Basel in Basel

Written by Customer Service on June 6, 2020. Posted in Public Companies.

MCH Group sagt die Art Basel im September 2020 abDie MCH Group sieht sich angesichts der aktuellen globalen Rahmenbedingungen gezwungen, die Durchführung der auf den 17. bis 20. September 2020 verschobenen Art Basel in Basel und der Design Miami Basel abzusagen. Der Entscheid zur Absage der Art Basel ist nach ausführlichen Beratungen mit vielen Galeristen, Sammlern, Partnern und externen Experten der Art Basel getroffen worden. Ausschlaggebend dafür sind die grundsätzlichen Gesundheits- und Sicherheitsrisiken für alle Beteiligten, die finanziellen Risiken für Aussteller und Partner, die anhaltenden Behinderungen des internationalen Reiseverkehrs sowie die Tatsache, dass das regulatorische Umfeld von Grossveranstaltungen in der Schweiz noch nicht geregelt ist.Marc Spiegler, Mitglied des Executive Board der MCH Group und Global Director...

Media Release | MCH Group | Art Basel in Basel

Written by Customer Service on June 6, 2020. Posted in Public Companies.

MCH Group Cancels Upcoming Art Basel Show in September 2020In view of the current global conditions, MCH Group has no option but to cancel the upcoming editions of Art Basel in Basel and Design Miami Basel, which had been postponed to mid-September 2020. The decision to cancel Art Basel was made after extensive consultation with many Art Basel gallerists, collectors, partners, as well as external experts. The primary considerations were the fundamental health and safety risks for everyone involved, the financial risks for exhibitors and partners, the ongoing impediments to international travel, and the fact that the regulatory environment around large-scale events in Switzerland has yet to be finalized.Marc Spiegler, Member of MCH Group’s Executive Board and Global Director Art Basel, explains: “We are aware that our galleries...

Media Release | MCH Group | Art Basel in Basel

Written by Customer Service on June 6, 2020. Posted in Public Companies.

Hexagon Mobile Pipeline® to virtually connect communities and industries to pipeline gas in the US

Written by Customer Service on June 6, 2020. Posted in Public Companies.

Hexagon Mobile Pipeline®, a Hexagon Composites subsidiary, has received a substantial contract for TITAN® 53 transport modules from Xpress Natural Gas LLC (XNG) a leading full-service provider of compressed natural gas (CNG). The strategic agreement has a total value of USD 7.3 million (approx. NOK 70.2 million) and includes additional purchase and rental options through 2021. The TITAN® 53 large-capacity Mobile Pipeline® modules will serve virtual interconnect projects providing natural gas to communities and industries that do not have access to sufficient pipeline capacity in the US.“Since XNG started operations in early 2013, Hexagon’s Titan products have proven to be high-quality products that deliver safety, reliability and performance,” says John Nahill, CEO and co-founder of Xpress Natural Gas. “The higher...

Celldex’s KIT Inhibitor CDX-0159 Demonstrates Profound, Sustained Dose-dependent Reductions in Plasma Tryptase—an Indicator of Mast Cell Burden—and a Favorable Safety Profile

Written by Customer Service on June 6, 2020. Posted in Public Companies.

–Data strongly support expanding development into mast cell driven diseases––Data presented in a late-breaking session at EAACI Annual Congress 2020–HAMPTON, N.J., June 06, 2020 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced results from the Company’s Phase 1 randomized, double-blind, placebo-controlled, dose escalation study of KIT inhibitor CDX-0159 in healthy subjects. Data (presentation #1829) were featured in a late breaking presentation today at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2020.CDX-0159 demonstrated a favorable safety profile as well as profound and durable reductions of plasma tryptase, consistent with systemic mast cell suppression. A single dose of CDX-0159 induced dose-dependent tryptase reduction below the level of...

Hereditary Angioedema Patients Report Breakthrough Attacks on Current Injectable/Infused Prophylaxis Medication

Written by Customer Service on June 6, 2020. Posted in Public Companies.

RESEARCH TRIANGLE PARK, N.C., June 06, 2020 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today presented findings from two patient surveys conducted to gain insights into patients’ current hereditary angioedema (HAE) treatment expectations, experience and satisfaction. Patient-reported attack history shows patients treated with current injectable or infused prophylactic medications (Takhzyro®, Haegarda®, Cinryze®) continue to experience breakthrough attacks with a mean ranging from 0.9 to 1.8 attacks over the three months prior to survey.In addition, the majority of patients surveyed did not expect to have zero attacks even when taking prophylaxis therapy.The data were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Digital Congress.“While the injectable and infused medications introduced...

Long-term (48-week) Data Show Treatment with Berotralstat Provides Robust and Durable Reductions in HAE Attacks and Improvements in Quality of Life Scores

Written by Customer Service on June 6, 2020. Posted in Public Companies.

RESEARCH TRIANGLE PARK, N.C., June 06, 2020 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced new data from the APeX-2 and APeX-S clinical trials, which showed that hereditary angioedema (HAE) patients taking oral, once-daily berotralstat experienced sustained decreases in their attack frequency and improvements in quality of life (QoL) scores over 48 weeks. Berotralstat was also safe and generally well-tolerated over 48 weeks in both APeX-2 and APeX-S.The data were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Digital Congress.“As HAE patients continue in our long‑term clinical trials, we are seeing reductions in attack rate and increases in QoL scores which highlight the impact oral, once-daily berotralstat could have in reducing the burden of disease for patients currently...

Akcea и Ionis объявляют о публикации долгосрочных клинических данных TEGSEDI® у пациентов с полиневропатией, вызванной наследственным транстиретин-амилоидозом, демонстрирующих устойчивые улучшения и даже большую стабилизацию у пациентов, приступающих к лечению раньше других.

Written by Customer Service on June 6, 2020. Posted in Public Companies.

Результаты продолжающегося открытого дополнительного (OLE) исследования краеугольного исследования NEURO–TTR, опубликованного в Европейском журнале неврологии, показывают, что у пациентов, принимавших TEGSEDI® (инотерсен), наблюдались устойчивое улучшение невропатического прогрессирования через 39 месяцев терапии и клинически соответствующие улучшения в показателях качества жизни по сравнению с естественным протеканием болезни без вмешательства.Новых сигналов безопасности обнаружено не былo.TEGSEDI представляет собой домашнюю подкожную инъекцию.БОСТОН и КАРЛСБАД, Калифорния, June 06, 2020 (GLOBE NEWSWIRE) — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS ) и Akcea Therapeutics, Inc. (NASDAQ: AKCA), контрольный пакет акций которой пренадлежит Ionis Pharmaceuticals, Inc., сегодня анонсировали публикацию долгосрочных данных открытого...

Opiant Pharmaceuticals Statement on U.S. District Court Decision

Written by Customer Service on June 6, 2020. Posted in Public Companies.

SANTA MONICA, Calif., June 05, 2020 (GLOBE NEWSWIRE) — Today, the U.S. District Court for the District of New Jersey entered a decision in the patent litigation regarding NARCAN® (naloxone HCl) Nasal Spray 4mg/spray product. The Court ruled in favor of the Defendants, Teva Pharmaceuticals Industries Ltd. Opiant’s commercial partner Emergent BioSolutions, intends to appeal the decision to the Court of Appeals for the Federal Circuit.“While we are disappointed by the decision today, we are mindful of the important role NARCAN® Nasal Spray plays across the United States in helping our communities save lives from opioid overdose,” said Roger Crystal, M.D., President and Chief Executive Officer of Opiant. “With our pipeline and strong financial position, we remain committed to develop best-in-class medicines for addiction and overdose.”About Opiant...

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30

Day: June 6, 2020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice